WHARTEXA 40B HUC-MSCs Exosome
Whartexa 40B HUC-MSCs Exosome is an ultra high-concentration regenerative extracellular vesicle formulation developed by Nanoventra under the proprietary Whartexa Line.
Derived from carefully processed Wharton’s Jelly Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs), this advanced exosome platform is engineered using precision extracellular vesicle isolation technologies, controlled purification workflows, and cryopreservation methodologies intended to support superior vesicle integrity, biological stability, and advanced regenerative signaling performance.
Human-Derived Exosomes From:*
Wharton’s Jelly
Product image shown represents the finalized Whartexa formulation. Actual presentation may vary slightly depending on packaging updates, preservation configuration, and production optimization protocols.
Details
Quality
Related Products
Details
WHARTEXA 40B HUC-MSCs Exosome
Nanoventra develops advanced HUC-MSC-derived extracellular vesicle systems through controlled purification technologies, laboratory-grade vesicle isolation methodologies, and precision cryopreservation workflows designed to maintain extracellular vesicle integrity, biological consistency, and regenerative signaling stability.
​
Whartexa 40B is formulated from carefully processed Wharton’s Jelly umbilical biological sources and represents an ultra high-concentration formulation within the proprietary Whartexa regenerative biotechnology platform.
​
This formulation is optimized for professional regenerative integration environments requiring intensified extracellular vesicle concentration systems, advanced nano-vesicle handling methodologies, precision biological preservation support, and biotechnology-oriented consistency standards.
​
Human umbilical cord-derived extracellular vesicles continue to gain recognition within regenerative biotechnology, advanced extracellular signaling research, scalp-focused regenerative systems, dermatological integration science, and next-generation regenerative formulation development platforms.
Key Features
-
Proprietary Whartexa regenerative exosome platform
-
Human Wharton’s Jelly HUC-MSC-derived extracellular vesicles
-
40 Billion particle concentration system
-
Ultra high-concentration regenerative formulation
-
Precision extracellular vesicle purification workflows
-
Controlled laboratory-grade isolation methodologies
-
Cryopreserved formulation maintained at −20°C
-
Enhanced vesicle stability and biological consistency
-
Professional regenerative and biotechnology-oriented integration
-
Advanced nano-vesicle handling and preservation systems
-
Research-focused extracellular vesicle preparation protocols
Quality
Specifications
All Whartexa 40B HUC-MSCs Exosome formulations undergo advanced scientific quality verification through multi-stage extracellular vesicle processing systems, laboratory-oriented preparation workflows, and controlled purification methodologies.
​
Each preparation is processed under sterile laboratory-grade conditions with focused attention toward:
-
extracellular vesicle integrity
-
particle concentration consistency
-
biological stability
-
purification precision
-
advanced handling reproducibility
​
Nanoventra applies biotechnology-oriented quality methodologies intended to support formulation consistency across regenerative extracellular vesicle systems and advanced exosome engineering platforms.
​
The Whartexa Line represents Nanoventra’s premium regenerative biotechnology division focused on advanced extracellular vesicle refinement, precision biological preservation systems, and controlled exosome formulation development.
Storage & Handling
-
Recommended storage temperature: −20°C
-
Maintain cryopreserved conditions during handling
-
Avoid repeated freeze-thaw exposure
-
Professional laboratory-oriented handling recommended